Skip to main content
SpringerLink
Log in
Book cover

Urogenitale Carcinome pp 135–178Cite as

Blasencarcinome und Carcinome des Übergangsepithels

  • Chapter

  • 25 Accesses

Part of the book series: Onkologie heute ((ONKOLOGIE))

Zusammenfassung

In den westlichen Industrieländern machen Blasencarcinome rund 2–4% aller diagnostizierten Malignome aus und repräsentieren mit einer Inzidenz von 12–23 Neuerkrankungen pro 100.000 Einwohner und Jahr den zweithäuflgsten urologischen Tumor und die vierthäufigste maligne Neoplasie bei Männern (Greenlee et al. 2000). Die Geschlechtsverteilung Männer/Frauen beträgt etwa 3: 1, der Häufigkeitsgipfel liegt in der 7. Dekade. Gehäuft treten Blasencarcinome in westlichen Industrieländern besonders im urbanen Bereich und bei Personen mit hohem ökonomischem Status auf. In den letzten zwei Jahrzehnten ist die Mortalität an Urothelcarcinomen trotz deutlich steigender Inzidenz durch verbesserte diagnostische und therapeutische Ansätze deutlich zurückgegangen (Devesa et al. 1995). Andererseits repräsentiert die scheinbar steigende Inzidenz auch das Resultat der verbesserten Früherkennung und pathologischen Diagnostik, welche zu einer zunehmenden Erkennung nichtinvasiver Carcinome führt (Doll und Peto 1981). Zum Zeitpunkt der Diagnosestellung sind über drei Viertel aller Blasencarcinome noch auf das Organ beschränkt, 19% sind regional ausgedehnt und 3% bereits metastasiert.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abratt RP, Tucker RD, Barnes DR (1983) Radical irradiation of T2 grade III and T3 bladder cancer-tumor response and prognosis. Int J Radiat Oncol Biol Phys 9: 1213–1215.

    Article  PubMed  CAS  Google Scholar 

  2. Advanced Bladder Cancer Overview Collaboration (2000) Neoadjuvant cisplatin for advanced bladder cancer. Cochrane Database Syst Rev 2.

    Google Scholar 

  3. Ali-el-Dein B, el-Baz M, Aly AN, Shamaa S, Ashamallah A (1997a) Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pTl): A randomized prospective study. J Urol 158: 68–73; Discussion 73-74.

    Article  PubMed  CAS  Google Scholar 

  4. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A (1997b) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pTl transitional-cell bladder tumours: A prospective, randomized controlled study [see Comments]. Br J Urol 79: 731–735.

    Article  PubMed  CAS  Google Scholar 

  5. Ali-el-Dein B, Nabeeh A, Ismail EH, Ghoneim MA (1999) Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study. J Urol 162: 339–342.

    Article  PubMed  CAS  Google Scholar 

  6. Amberson JB, Laino JP (1993) Image cytometric deoxyribonucleic acid analysis of urine specimens as an adjunct to visual cytology in the detection of urothelial cell carcinoma. J Urol 149: 42–45.

    PubMed  CAS  Google Scholar 

  7. Babaian RJ, Johnson DE, Llamas L, Ayala AG (1980) Metastases from transitional cell carcinoma of urinary bladder. Urology 16: 142–144.

    Article  PubMed  CAS  Google Scholar 

  8. Badalament RA, Herr HW, Wong GY, et al. (1987) A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5: 441–449.

    PubMed  CAS  Google Scholar 

  9. Bajorin DF, Dodd PM, Mazumdar M, et al. (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181.

    PubMed  CAS  Google Scholar 

  10. Bane BL, Rao JY, Hemstreet GP (1996) Pathology and staging of bladder cancer. Semin Oncol 23: 546–570.

    PubMed  CAS  Google Scholar 

  11. Barnes RW, Dick AL, Hadley HL, Johnston OL (1977) Survival following transurethral resection of bladder carcinoma. Cancer Res 37: 2895–2897.

    PubMed  CAS  Google Scholar 

  12. Bell CR, Lydon A, Kernick V, et al. (1999) Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-centre status [see Comments]. BJU Int 83: 613–618.

    Article  PubMed  CAS  Google Scholar 

  13. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW (1993) Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase Ml (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159–1164.

    Article  PubMed  CAS  Google Scholar 

  14. Bellmunt J, Guillem V, Paz-Ares L, et al. (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18: 3247–3255.

    PubMed  CAS  Google Scholar 

  15. Bellmunt J, Ribas A, Eres N, et al. (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80: 1966–1972.

    Article  PubMed  CAS  Google Scholar 

  16. Bi W, Rao JY, Hemstreet GP, et al. (1993) Field molecular epidemiology. Feasibility of monitoring for the malignant bladder cell phenotype in a benzidine-exposed occupational cohort. J Occup Med 35: 20–27.

    PubMed  CAS  Google Scholar 

  17. Birkenhake S, Martus P, Kuhn R, Schrott KM, Sauer R (1998) Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer [see Comments]. Strahlenther Onkol 174: 121–127.

    Article  PubMed  CAS  Google Scholar 

  18. Bissada NK, Morcos RR, Morgan WM, Hanash KA (1995) Ureterosigmoidostomy: Is it a viable procedure in the age of continent urinary diversion and bladder substitution? [see Comments]. J Urol 153: 1429–1431.

    Article  PubMed  CAS  Google Scholar 

  19. Bloom HJ, Hendry WF, Wallace DM, Skeet RG (1982) Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54: 136–151.

    Article  PubMed  CAS  Google Scholar 

  20. Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A, Martorana G (1994) Carbo-platin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer 73: 1932–1936.

    Article  PubMed  CAS  Google Scholar 

  21. Bonner RB, Hemstreet GPd, Fradet Y, Rao JY, Min KW, Hurst RE (1993) Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 72: 2461–2469.

    Article  PubMed  CAS  Google Scholar 

  22. Bono AV, Benvenuti C, Damiano G, Lovisolo J (1994) Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer. Urology 44: 329–334; Discussion 334-335.

    Article  PubMed  CAS  Google Scholar 

  23. Bouffioux C, Kurth KH, Bono A, et al. (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus longterm treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153: 934–941.

    Article  PubMed  CAS  Google Scholar 

  24. Brannan W, Ochsner MG, Fuselier Jr. HA, Landry GR (1978) Partial cystectomy in the treatment of transitional cell carcinoma of the bladder. J Urol 119: 213–215.

    PubMed  CAS  Google Scholar 

  25. Bredael JJ, Croker BP, Glenn JF (1980) The curability if invasive bladder cancer treated by radical cystectomy. Eur Urol 6: 206–210.

    PubMed  CAS  Google Scholar 

  26. Bricker EM (1978) The evolution of the ileal segment bladder substitution operation. Am JSurg 135: 834–841.

    Article  CAS  Google Scholar 

  27. Britton JP, Dowell AC, Whelan P (1989) Dipstick haematuria and bladder cancer in men over 60: Results of a community study [see Comments]. Bmj 299: 1010–1012.

    Article  PubMed  CAS  Google Scholar 

  28. Bruni GS, Posca T, Celiento G (1998) Gemcitabine and navelbine in elderly patients with bladder cancer: Pilot study. Proc Am Soc Clin Oncol: A307.

    Google Scholar 

  29. Bui TT, Schellhammer PF (1997) Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49: 687–690; Discussion 690-691.

    Article  PubMed  CAS  Google Scholar 

  30. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sei USA 86: 7696–7700.

    Article  CAS  Google Scholar 

  31. Cancer AJCo (1997) AJCC Cancer Staging Manual, 5th Ed. Lippincott-Raven Publishers, Philadelphia, PA.

    Google Scholar 

  32. Carles J, Nogue M, Domenech M, et al. (2000) Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59: 24–27.

    Article  PubMed  CAS  Google Scholar 

  33. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364–1369.

    Article  PubMed  CAS  Google Scholar 

  34. Clinton SK, Canto E, O’Donnell MA (2000) Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 27: 147–155.

    Article  PubMed  CAS  Google Scholar 

  35. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P (1996) Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155: 1227–1232.

    Article  PubMed  CAS  Google Scholar 

  36. Colombo R, Da Pozzo LF, Lev A, et al. (1998) Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 159: 783–787.

    Article  PubMed  CAS  Google Scholar 

  37. Coppin CM, Gospodarowicz MK, James K, et al. (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901–2907.

    PubMed  CAS  Google Scholar 

  38. Crawford ED, Skinner DG (1980) Salvage cystectomy after irradiation failure. J Urol 123: 32–34.

    PubMed  CAS  Google Scholar 

  39. Cummings KB, Barone JG, Ward WS (1992) Diagnosis and staging of bladder cancer. Urol Clin North Am 19: 455–465.

    PubMed  CAS  Google Scholar 

  40. Dandekar NP, Tongaonkar HB, Dalal AV, Kulkarni JN, Kamat MR (1995) Partial cystectomy for invasive bladder cancer. J Surg Oncol 60: 24–29.

    Article  PubMed  CAS  Google Scholar 

  41. Dean PJ, Murphy WM (1985) Importance of urinary cytology and future role of flow cytometry. Urology 26: 11–15.

    PubMed  CAS  Google Scholar 

  42. Decensi A, Torrisi R, Bruno S, et al. (2000) Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point [In Process Citation]. Cancer Epidemiol Biomarkers Prev 9: 1071–1078.

    PubMed  CAS  Google Scholar 

  43. De Reijke TM, De Boer EC, Kurth KH, Schamhart DH (1999) Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: Can it predict the optimal number of instillations? J Urol 161: 67–71.

    Article  PubMed  Google Scholar 

  44. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni Jr. JF (1995) Recent cancer trends in the United States [see Comments]. J Natl Cancer Inst 87: 175–182.

    Article  PubMed  CAS  Google Scholar 

  45. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. (1999) Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 10: 1385–1388.

    Article  PubMed  CAS  Google Scholar 

  46. Dodd PM, McCaffrey JA, Herr H, et al. (1999) Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17: 2546–2552.

    PubMed  CAS  Google Scholar 

  47. Dodd PM, McCaffrey JA, Hilton S, et al. (2000) Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unre-sectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18: 840–846.

    PubMed  CAS  Google Scholar 

  48. Doll R, Peto R (1981) The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191–1308.

    PubMed  CAS  Google Scholar 

  49. Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU (1996) Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol 23: 614–620.

    PubMed  CAS  Google Scholar 

  50. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study. J Clin Oncol 18: 1058–1061.

    PubMed  CAS  Google Scholar 

  51. Duchesne GM, Bolger JJ, Griffiths GO, et al. (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 47: 379–388.

    Article  PubMed  CAS  Google Scholar 

  52. Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 7: 299–310.

    Article  PubMed  CAS  Google Scholar 

  53. Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A (1994) Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30: 261–266.

    Article  PubMed  CAS  Google Scholar 

  54. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Gandour-Edwards R, De Vere White RW (2000) Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation. Urology 55: 521–525.

    Article  PubMed  CAS  Google Scholar 

  55. Eisenberger CF, Schoenberg M, Fitter D, Marshall FF (1999) Orthotopic ileocolic neobladder reconstruction following radical cystectomy: History, technique and results of the Johns Hopkins experience, 1986–1998. Urol Clin North Am 26: 149–156, ix.

    Article  PubMed  CAS  Google Scholar 

  56. Elcock M, Morgan RW (1993) Update on artificial sweeteners and bladder cancer. Regul Toxicol Pharmacol 17: 35–43.

    Article  PubMed  CAS  Google Scholar 

  57. Englander LS (1984) Histopathology of bladder cancer and dysplasia. Urology 23: 27–28.

    Article  PubMed  CAS  Google Scholar 

  58. Esrig D, Elmajian D, Groshen S, et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer [see Comments]. N Engl J Med 331: 1259–1264.

    Article  PubMed  CAS  Google Scholar 

  59. Evans RA, Texter Jr. JH (1975) Partial cystectomy in the treatment of bladder cancer. J Urol 114: 391–393.

    PubMed  CAS  Google Scholar 

  60. Farah R, Chodak GW, Vogelzang NJ, et al. (1991) Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys 20: 413–417.

    Article  PubMed  CAS  Google Scholar 

  61. Ferrari P, Castagnetti G, Pollastri CA, Ferrari G, Tavoni F, Grassi D (1992) Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferonalpha 2b versus interferon-alpha 2b with epirubicin. Anticancer Drugs 3Suppl 1: 25–27.

    Article  PubMed  Google Scholar 

  62. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF (1999) 5-Amino-levulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 53:77–81.

    Article  PubMed  CAS  Google Scholar 

  63. Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection. J Urol 135: 920–922.

    PubMed  CAS  Google Scholar 

  64. Flamm J, Donner G, Bucher A, Holtl W, Albrecht W, Havelec L (1994) Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 33: 138–143.

    PubMed  CAS  Google Scholar 

  65. Fossa SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S (1993) Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72: 3036–3043.

    Article  PubMed  CAS  Google Scholar 

  66. Frazier HA, Robertson JE, Paulson DF (1992) Complications of radical cystectomy and urinary diversion: A retrospective review of 675 cases in 2 decades. J Urol 148: 1401–1405.

    PubMed  CAS  Google Scholar 

  67. Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer [see Comments]. J Urol 155: 495–499; Discussion 499-500.

    Article  PubMed  CAS  Google Scholar 

  68. Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson SA (1984) Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 309: 464–466.

    Article  PubMed  CAS  Google Scholar 

  69. Fung CY, Shipley WU, Young RH, et al. (1991) Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy [see Comments]. J Clin Oncol 9: 1533 1542.

    PubMed  Google Scholar 

  70. Galetti TP, Pontes JE, Montie J, Medendorp SV, Bukowski R (1989) Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: Results and followup. J Urol 142: 1211–1214; Discussion 1214-1215.

    PubMed  CAS  Google Scholar 

  71. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A (1991) Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67: 1525–1531.

    Article  PubMed  CAS  Google Scholar 

  72. Ghoneim MA, Shaaban AA, Mahran MR, Kock NG (1992) Further experience with the urethral Kock pouch. J Urol 147: 361–365.

    PubMed  CAS  Google Scholar 

  73. Gilbert HA, Logan JL, Kagan AR, et al. (1978) The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol 119: 488–492.

    PubMed  CAS  Google Scholar 

  74. Given RW, Parsons JT, McCarley D, Wajsman Z (1995) Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 46: 499–504; Discussion 504-505.

    Article  PubMed  CAS  Google Scholar 

  75. Glashan RW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144: 658–661.

    PubMed  CAS  Google Scholar 

  76. Goldberg MR, Heimbrook DC, Russo P, et al. (1995) Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1: 57–61.

    PubMed  CAS  Google Scholar 

  77. Gonzalez-Zulueta M, Ruppert JM, Tokino K, et al. (1993) Microsatellite instability in bladder cancer. Cancer Res 53: 5620–5623.

    PubMed  CAS  Google Scholar 

  78. Gospodarowicz MK, Rider WD, Keen CW, et al. (1991) Bladder cancer: Long-term-follow-up results of patients treated with radical radiation. Clin Oncol (R Coll Radiol) 3: 155–161.

    Article  CAS  Google Scholar 

  79. Gough AC, Miles JS, Spurr NK, et al. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347: 773–776.

    Article  PubMed  CAS  Google Scholar 

  80. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7–33.

    Article  PubMed  CAS  Google Scholar 

  81. Greven KM, Solin LJ, Hanks GE (1990) Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 65: 908–912.

    Article  PubMed  CAS  Google Scholar 

  82. Gschwend JE, Fair WR, Vieweg J (2000) Radical cystectomy for invasive bladder cancer: Contemporary results and remaining controversies. Eur Urol 38: 121–130.

    Article  PubMed  CAS  Google Scholar 

  83. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PH (1984) Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 56: 668–672.

    Article  PubMed  CAS  Google Scholar 

  84. Hall RR, MACWP, EORTC GU Group (1996) Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial. Proc Am Soc Clin Oncol 15: 612.

    Google Scholar 

  85. Harker WG, Meyers FJ, Freiha FS, et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3:1463–1470.

    PubMed  CAS  Google Scholar 

  86. Hautmann RE, De Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T (1999) The ileal neobladder: Complications and functional results in 363 patients after 11 years of followup [see Comments]. J Urol 161: 422–427; Discussion 427-428.

    Article  PubMed  CAS  Google Scholar 

  87. Hautmann RE, Simon J (1999) Ileal neobladder and local recurrence of bladder cancer: Patterns of failure and impact on function in men [see Comments]. J Urol 162: 1963–1966.

    Article  PubMed  CAS  Google Scholar 

  88. Hemstreet 3rd GP, Rao J, Hurst RE, et al. (1996) G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. J Cell Biochem Suppl 25: 197–204.

    Article  PubMed  Google Scholar 

  89. Hemstreet GP, Rollins S, Jones P, et al. (1991) Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J Urol 146: 1525–1529.

    PubMed  Google Scholar 

  90. Heney NM, Ahmed S, Flanagan MJ, et al. (1983) Superficial bladder cancer: Progression and recurrence. J Urol 130: 1083–1086.

    PubMed  CAS  Google Scholar 

  91. Henry K, Miller J, Mori M, Loening S, Fallon B (1988) Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140: 964–967.

    PubMed  CAS  Google Scholar 

  92. Herr HW (1987) Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 138: 1162–1163.

    PubMed  CAS  Google Scholar 

  93. Herr HW (1992) Staging invasive bladder tumors. J Surg Oncol 51: 217–220.

    Article  PubMed  CAS  Google Scholar 

  94. Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors [see Comments]. J Urol 162: 74–76.

    Article  PubMed  CAS  Google Scholar 

  95. Herr HW, Bajorin DF, Scher HI (1998) Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 16: 1298–1301.

    PubMed  CAS  Google Scholar 

  96. Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE (1999) Can p53 help select patients with invasive bladder cancer for bladder preservation? [see Comments]. J Urol 161: 20–22; Discussion 22-23.

    Article  PubMed  CAS  Google Scholar 

  97. Herr HW, Pinsky CM, Whitmore Jr. WF, Sogani PC, Oettgen HF, Melamed MR (1986) Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 135: 265–267.

    PubMed  CAS  Google Scholar 

  98. Herr HW, Scher HI (1994) Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12: 975–980.

    PubMed  CAS  Google Scholar 

  99. Herr HW, Schwalb DM, Zhang ZF, et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404–1408.

    PubMed  CAS  Google Scholar 

  100. Herr HW, Whitmore Jr. WF, Morse MJ, Sogani PC, Russo P, Fair WR (1990) Neoadjuvant chemotherapy in invasive bladder cancer: The evolving role of surgery. J Urol 144: 1083–1088.

    PubMed  CAS  Google Scholar 

  101. Hollister Jr. D, Coleman M (1980) Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. Jama 244: 2065–2067.

    Article  PubMed  Google Scholar 

  102. Hopkins SC, Ford KS, Soloway MS (1983) Invasive bladder cancer: Support for screening. J Urol 130: 61–64.

    PubMed  CAS  Google Scholar 

  103. Hoskin PJ, Saunders MI, Dische S (1999) Hypoxie radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 86: 1322–1328.

    Article  PubMed  CAS  Google Scholar 

  104. Housset M, Maulard C, Chretien Y, et al. (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150–2157.

    PubMed  CAS  Google Scholar 

  105. Huan SD, Aitken SE, Stewart DJ (1995) A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. Ann Oncol 6: 836–837.

    PubMed  CAS  Google Scholar 

  106. Huland E, Schwaibold H, Klan R, Huland H (1995) Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer. Urology 45: 54–57; Discussion 57-58.

    Article  PubMed  CAS  Google Scholar 

  107. Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T (1995) Long-term results with M-VAC for advanced urothelial cancer: High relapse rate and low survival in patients with a complete response. Br J Urol 76: 321–324.

    Article  PubMed  CAS  Google Scholar 

  108. Imai T, Kimura M, Takeda M, Tomita Y (1995) Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. Br J Cancer 71: 69–72.

    Article  PubMed  CAS  Google Scholar 

  109. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial [see Comments] [published erratum appears in Lancet 1999 Nov 6; 354(9190): 1650]. Lancet 354: 533–540.

    Article  Google Scholar 

  110. Jacobs SC, Menashe DS, Mewissen MW, Lipchik EO (1989) Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 64: 388–391.

    Article  PubMed  CAS  Google Scholar 

  111. Jakse G, Loidl W, Seeber G, Hofstadter F (1987) Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor? J Urol 137: 39–43.

    PubMed  CAS  Google Scholar 

  112. Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al. (1997) Intravesical immunopro-phylaxis in recurrent superficial bladder cancer (Stage Tl): Multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 50: 529–535.

    Article  PubMed  CAS  Google Scholar 

  113. Jurincic CD, Engelmann U, Gasch J, Klippel KF (1988) Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: A randomized study. J Urol 139: 723–726.

    PubMed  CAS  Google Scholar 

  114. Jurincic-Winkler C, Metz KA, Beuth J, Sippel J, Klippel KF (1995) Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guerin (BCG) instillation on carcinoma in situ of the urinary bladder. Anticancer Res 15: 2771–2776.

    PubMed  CAS  Google Scholar 

  115. Kaasinen E, Rintala E, Pere AK, et al. (2000) Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 164: 47–52.

    Article  PubMed  CAS  Google Scholar 

  116. Kachnic LA, Kaufman DS, Heney NM, et al. (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15: 1022–1029.

    PubMed  CAS  Google Scholar 

  117. Kalble T, Mohring K, Ikinger U, Riedasch G, Staehler G (1991) Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study. Urologe [A] 30: 118–121.

    CAS  Google Scholar 

  118. Kamat AM, Lamm DL (1999) Chemoprevention of urological cancer [see Comments]. J Urol 161: 1748–1760.

    Article  PubMed  CAS  Google Scholar 

  119. Kantoff PW, Zeitman AL, Winshow K (1997) Bladder cancer. In: Holland JF, Morton DL (eds) Cancer Medicine. Williams and Wilkins, Baltimore, MD, S. 2105–2123.

    Google Scholar 

  120. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM (1991) Stage Tl bladder cancer: Grade is the primary determinant for risk of muscle invasion. J Urol 146: 28–31.

    PubMed  CAS  Google Scholar 

  121. Kaufman D, Raghavan D, Carducci M, et al. (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921–1927.

    PubMed  CAS  Google Scholar 

  122. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT (1993) Selective bladder preservation by combination treatment of invasive bladder cancer [see Comments]. N Engl J Med 329: 1377–1382.

    Article  PubMed  CAS  Google Scholar 

  123. Khaled HM, Hamza MR, Mansour O, Gaafar R, Zaghloul MS (2000) A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma [In Process Citation]. Eur J Cancer 36Suppl 2: 34–37.

    Article  PubMed  Google Scholar 

  124. Khandekar JD, Elson PJ, DeWys WD, Slayton RE, Harris DT (1985) Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxombicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. J Clin Oncol 3: 539–545.

    PubMed  CAS  Google Scholar 

  125. Krege S, Giani G, Meyer R, Otto T, Rubben H (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics [see Comments]. J Urol 156: 962–966.

    Article  PubMed  CAS  Google Scholar 

  126. Kriegmair M, Zaak D, Stepp H, Baumgartner R, Knuechel R, Hofstetter A (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminole-vulinic acid-induced fluorescence endoscopy. Eur Urol 36: 386–392.

    Article  PubMed  CAS  Google Scholar 

  127. Kurth K, Tunn U, Ay R, et al. (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of an European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158: 378–384.

    Article  PubMed  CAS  Google Scholar 

  128. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573–580.

    PubMed  CAS  Google Scholar 

  129. Lamm DL, Blumenstein BA, Crawford ED, et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205–1209.

    Article  PubMed  CAS  Google Scholar 

  130. Lamm DL, Blumenstein BA, Crissman JD, et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163: 1124–1129.

    Article  PubMed  CAS  Google Scholar 

  131. Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, De Haven JI (1994) Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 151:21–26.

    PubMed  CAS  Google Scholar 

  132. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444–1450.

    Article  PubMed  CAS  Google Scholar 

  133. Lamm DL, van der Meijden PM, Morales A, et al. (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596–600.

    PubMed  CAS  Google Scholar 

  134. Leissner J, Stein R, Hohenfellner R, et al. (1999) Radical cystoprostatectomy combined with Mainz pouch bladder substitution to the urethra: Long-term results. BJUInt 83: 964–970.

    Article  CAS  Google Scholar 

  135. Lerner SP, Skinner DG, Lieskovsky G, et al. (1993) The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: Long-term results. J Urol 149: 758–764; Discussion 764-765.

    PubMed  CAS  Google Scholar 

  136. Levinson AK, Johnson DE, Wishnow KI (1990) Indications for urethrectomy in an era of continent urinary diversion. J Urol 144: 73–75.

    PubMed  CAS  Google Scholar 

  137. Loehrer PJ, DeMulder PHM (1997) Management of metastatic bladder cancer. In: Raghaven D, Scher HJ, Leibel SA (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, PA, S. 299–305.

    Google Scholar 

  138. Loehrer Sr. PJ, Einhorn LH, Elson PJ, et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study [published erratum appears in J Clin Oncol 1993 Feb; 11(2): 384]. J Clin Oncol 10: 1066–1073.

    PubMed  Google Scholar 

  139. Logothetis C, Swanson D, Amato R, et al. (1996) Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241–1245.

    Article  PubMed  CAS  Google Scholar 

  140. Logothetis CJ, Dexeus FH, Finn L, et al. (1990a) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050–1055.

    PubMed  CAS  Google Scholar 

  141. Logothetis CJ, Dexeus FH, Sella A, et al. (1990b) Escalated therapy for refractory urothelial tumors: Methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82: 667–672.

    Article  PubMed  CAS  Google Scholar 

  142. Logothetis CJ, Finn LD, Smith T, et al. (1995) Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272–2277.

    PubMed  CAS  Google Scholar 

  143. Logothetis CJ, Johnson DE, Chong C, et al. (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: An update. J Clin Oncol 6: 1590–1596.

    PubMed  CAS  Google Scholar 

  144. Logothetis CJ, Samuels ML, Ogden S, et al. (1985) Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 134: 460–464.

    PubMed  CAS  Google Scholar 

  145. Lorusso V, Pollera CF, Antimi M, et al. (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34: 1208–1212.

    Article  PubMed  CAS  Google Scholar 

  146. Lundholm C, Norlen BJ, Ekman P, et al. (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma [see Comments]. J Urol 156: 372–376.

    Article  PubMed  CAS  Google Scholar 

  147. Lynch WJ, Jenkins BJ, Fowler CG, Hope-Stone HF, Blandy JP (1992) The quality of life after radical radiotherapy for bladder cancer. Br J Urol 70: 519–521.

    PubMed  CAS  Google Scholar 

  148. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group [see Comments]. J Urol 155: 1903–1906.

    Article  PubMed  CAS  Google Scholar 

  149. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124–1127.

    Article  PubMed  CAS  Google Scholar 

  150. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 153: 964–973.

    Article  PubMed  CAS  Google Scholar 

  151. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro Jr. L, et al. (1990) Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143: 502–506.

    PubMed  CAS  Google Scholar 

  152. Maru A, Akaza H, Isaka S, et al. (1987) Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: Cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder. Cancer Chemother Pharmacol 20: S44–S48.

    Article  PubMed  Google Scholar 

  153. Mazeron JJ, Crook J, Chopin D, et al. (1988) Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192. Int J Radiat Oncol Biol Phys 15:1323–1330.

    Article  PubMed  CAS  Google Scholar 

  154. McCaffrey JA, Hilton S, Mazumdar M, et al. (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853–1857.

    PubMed  CAS  Google Scholar 

  155. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H (1993) Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: Results of a controlled prospective trial with modified treatment schedule. J Urol 149: 744–748.

    PubMed  CAS  Google Scholar 

  156. Melekos MD, Zarakovitis IE, Fokaefs ED, et al. (1996) Intravesical bacillus Calmette-Guerin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology 53: 281–288.

    Article  PubMed  CAS  Google Scholar 

  157. Messing EM, Young TB, Hunt VB, et al. (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45: 387–396; Discussion 396-397.

    Article  PubMed  CAS  Google Scholar 

  158. Messing EM, Young TB, Hunt VB, et al. (1992) Home screening for hematuria: Results of a multiclinic study. J Urol 148: 289–292.

    PubMed  CAS  Google Scholar 

  159. Michaud DS, Spiegelman D, Clinton SK, et al. (1999) Fluid intake and the risk of bladder cancer in men [see Comments]. N Engl J Med 340: 1390–1397.

    Article  PubMed  CAS  Google Scholar 

  160. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer [see Comments]. J Urol 163: 73–78.

    Article  PubMed  CAS  Google Scholar 

  161. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y (1995) Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 71: 831–835.

    Article  PubMed  CAS  Google Scholar 

  162. Mokarim A, Uetani M, Hayashi N, et al. (1997) Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 80: 1776–1785.

    Article  PubMed  CAS  Google Scholar 

  163. Moore MJ, Winquist EW, Murray N, et al. (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876–2881.

    PubMed  CAS  Google Scholar 

  164. Morrison AS, Buring JE, Verhoek WG, et al. (1984) An international study of smoking and bladder cancer. J Urol 131: 650–654.

    PubMed  CAS  Google Scholar 

  165. Norming U (1993) DNA flow cytometry: An update of its use in assessing prognosis for transitional cell cancer of the bladder. Semin Urol 11: 154–163.

    PubMed  CAS  Google Scholar 

  166. Novick AC, Stewart BH (1976) Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol 116: 570–574.

    PubMed  CAS  Google Scholar 

  167. Nseyo UO, De Haven J, Dougherty TJ, et al. (1998a) Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: A long-term experience. J Clin Laser Med Surg 16: 61–68.

    PubMed  CAS  Google Scholar 

  168. Nseyo UO, Shumaker B, Klein EA, Sutherland K (1998b) Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J Urol 160: 39–44.

    Article  PubMed  CAS  Google Scholar 

  169. Nurmi M, Puntala P, Alanen A (1988) Evaluation of 144 cases of ileal conduits in adults. Eur Urol 15: 89–93.

    PubMed  CAS  Google Scholar 

  170. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749–752.

    PubMed  CAS  Google Scholar 

  171. Orsatti M, Curotto A, Canobbio L, et al. (1995) Alternating chemo-radiotherapy in bladder cancer: A conservative approach. Int J Radiat Oncol Biol Phys 33: 173–178.

    Article  PubMed  CAS  Google Scholar 

  172. Otto T, Bex A, Krege S, Walz PH, Rubben H (1997) Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): A clinical phase II study. Cancer 80: 465–470.

    Article  PubMed  CAS  Google Scholar 

  173. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A (1991) A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective? J Urol 146:32–35.

    PubMed  CAS  Google Scholar 

  174. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J (1997) Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75: 606–607.

    Article  PubMed  CAS  Google Scholar 

  175. Patterson AL, Greenberg RE, Weems L, et al. (2000) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56: 232–235.

    Article  PubMed  CAS  Google Scholar 

  176. Pawinski A, Sylvester R, Kurth KH, et al. (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156: 1934–1940, Discussion 1940-1941.

    Article  PubMed  CAS  Google Scholar 

  177. Peralta EA, Liu X, McCarthy TM, Wilson TG, Diamond DJ, Ellenhorn JD (1999) Immunotherapy of bladder cancer targeting P53 [see Comments]. J Urol 162: 1806–1811.

    Article  PubMed  CAS  Google Scholar 

  178. Pernot M, Hubert J, Guillemin F, et al. (1996) Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192). Radiother Oncol 38: 115–120.

    Article  PubMed  CAS  Google Scholar 

  179. Petrioli R, Frediani B, Manganelli A, et al. (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77: 344–351.

    Article  PubMed  CAS  Google Scholar 

  180. Pinsky CM, Camacho FJ, Kerr D, et al. (1985) Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial. Cancer Treat Rep 69: 47–53.

    PubMed  CAS  Google Scholar 

  181. Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313: 292–295.

    Article  PubMed  CAS  Google Scholar 

  182. Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5: 182–184.

    PubMed  CAS  Google Scholar 

  183. Poulsen AL, Horn T, Steven K (1998) Radical cystectomy: Extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 160: 2015–2019; Discussion 2020.

    Article  PubMed  CAS  Google Scholar 

  184. Pronzato P, Bertelli G, Bruna F, et al. (1997a) Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer. Anticancer Res 17:2325–2327.

    PubMed  CAS  Google Scholar 

  185. Pronzato P, Landucci M, Vaira F, Vigani A, Bertelli G (1995) Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder. Am J Clin Oncol 18: 223–225.

    Article  PubMed  CAS  Google Scholar 

  186. Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F (1997b) Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20: 519–521.

    Article  PubMed  CAS  Google Scholar 

  187. Prout Jr. GR, Griffin PP, Shipley WU (1979) Bladder carcinoma as a systemic disease. Cancer 43: 2532–2539.

    Article  PubMed  Google Scholar 

  188. Prout Jr. GR, Lin CW, Benson Jr. R, et al. (1987) Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med 317: 1251–1255.

    Article  PubMed  Google Scholar 

  189. Prout Jr. GR, Shipley WU, Kaufman DS, et al. (1990) Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol 144: 1128–1134; Discussion 1134-1136.

    PubMed  Google Scholar 

  190. Prout Jr. GR, Slack NH, Bross ID (1971) Preoperative irradiation as an adjuvant in the surgical management of invasive bladder carcinoma. J Urol 105: 223–231.

    PubMed  Google Scholar 

  191. Quilty PM, Duncan W, Chisholm GD, et al. (1986) Results of surgery following radical radiotherapy for invasive bladder cancer. Br J Urol 58: 396–405.

    Article  PubMed  CAS  Google Scholar 

  192. Radosevic-Jelic L, Pekmezovic T, Pavlovic-Cvetkovic L, Radulovic S, Petronic V (1999) Concomitant radiotherapy and carboplatin in locally advanced bladder cancer. Eur Urol 36: 401–405.

    Article  PubMed  CAS  Google Scholar 

  193. Rajala P, Liukkonen T, Raitanen M, et al. (1999) Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: A prospective randomized multicenter study — Finnbladder III. J Urol 161: 1133–1135; Discussion 1135–1136.

    Article  PubMed  CAS  Google Scholar 

  194. Ramakumar S, Bhuiyan J, Besse JA, et al. (1999) Comparison of screening methods in the detection of bladder cancer [see Comments]. J Urol 161: 388–394.

    Article  PubMed  CAS  Google Scholar 

  195. Reddy PK, Lange PH, Fraley EE (1991) Total bladder replacement using detubularized sigmoid colon: Technique and results. J Urol 145: 51–55.

    PubMed  CAS  Google Scholar 

  196. Redman BG, Smith DC, Flaherty L, Du W, Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16: 1844–1848.

    PubMed  CAS  Google Scholar 

  197. Resnick MI, O’Conor Jr. VJ (1973) Segmental resection for carcinoma of the bladder: Review of 102 patients. J Urol 109: 1007–1010.

    PubMed  CAS  Google Scholar 

  198. Reznikoff CA, Belair CD, Yeager TR, et al. (1996) A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23: 571–584.

    PubMed  CAS  Google Scholar 

  199. Richards B, Bastable JR, Freedman L, et al. (1983) Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy. Br J Urol 55: 386–391.

    Article  PubMed  CAS  Google Scholar 

  200. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O (1996) Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to Tl) superficial bladder cancer. Finnbladder Group [see Comments]. J Urol 156: 56–59; Discussion 59-60.

    Article  PubMed  CAS  Google Scholar 

  201. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O (1995) Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 154: 2050–2053.

    Article  PubMed  CAS  Google Scholar 

  202. Risch A, Wallace DM, Bathers S, Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231–236.

    Article  PubMed  CAS  Google Scholar 

  203. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK (2000) BCG intravesical instillations: Recommendations for side-effects management. Eur Urol 37: 33–36.

    Article  PubMed  Google Scholar 

  204. Rodrigues Netto Junior N, Lemos GC (1983) A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. J Urol 129: 33–34.

    Google Scholar 

  205. Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146: 36–39.

    PubMed  CAS  Google Scholar 

  206. Ross RK, Jones PA, Yu MC (1996) Bladder cancer epidemiology and pathogenesis. Semin Oncol 23: 536–545.

    PubMed  CAS  Google Scholar 

  207. Rostom YA, Chapet O, Russo SM, et al. (2000) Intra-operative electron radiotherapy as a conservative treatment for infiltrating bladder cancer [In Process Citation]. Eur J Cancer 36: 1781–1787.

    Article  PubMed  CAS  Google Scholar 

  208. Roth BJ, Dreicer R, Einhorn LH, et al. (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264–2270.

    PubMed  CAS  Google Scholar 

  209. Rotman M, Macchia R, Silverstein M, et al. (1987) Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion. Cancer 59: 710–714.

    Article  PubMed  CAS  Google Scholar 

  210. Rowland RG, Kropp BP (1994) Evolution of the Indiana continent urinary reservoir. J Urol 152:2247–2251.

    PubMed  CAS  Google Scholar 

  211. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139: 283–285.

    PubMed  CAS  Google Scholar 

  212. Sarosdy MF (1997) A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Eur Urol 31: 20–26.

    PubMed  CAS  Google Scholar 

  213. Saxman SB, Propert KJ, Einhorn LH, et al. (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15: 2564–2569.

    PubMed  CAS  Google Scholar 

  214. Schellhammer PF, Whitmore Jr. WF (1976) Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 115: 56–60.

    PubMed  CAS  Google Scholar 

  215. Scher H, Bahnson R, Cohen S, et al. (1998) NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Huntingt) 12: 225–271.

    CAS  Google Scholar 

  216. Scher H, Herr H, Sternberg C, et al. (1989) Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol 64: 250–256.

    Article  PubMed  CAS  Google Scholar 

  217. Scher HI, Yagoda A, Herr HW, et al. (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470–474.

    PubMed  CAS  Google Scholar 

  218. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB (1996) Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup [see Comments]. J Urol 155: 490–494.

    Article  PubMed  CAS  Google Scholar 

  219. See WA, Fuller JR (1992) Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am 19: 663–683.

    PubMed  CAS  Google Scholar 

  220. See WA, Miller JS, Williams RD (1989) Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: Mechanisms mediating intravesical recurrence due to implantation. Cancer Res 49: 5414–5418.

    PubMed  CAS  Google Scholar 

  221. See WA, Williams RD (1992) Urothelial injury and clotting cascade activation: Common denominators in particulate adherence to urothelial surfaces. J Urol 147: 541–548.

    PubMed  CAS  Google Scholar 

  222. Seidman AD, Scher HI, Gabrilove JL, et al. (1993) Dose-intensification of MV AC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer [see Comments]. J Clin Oncol 11: 408–414.

    PubMed  CAS  Google Scholar 

  223. Seidman AD, Scher HI, Heinemann MH, et al. (1991) Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68: 2561–2565.

    Article  PubMed  CAS  Google Scholar 

  224. Sekine H, Fukui I, Yamada T, Kojima S, Ohshima H (1996) Histological grading of carcinoma in situ of the bladder: Its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy [see Comments]. J Urol 155: 94–98; Discussion 98-99.

    Article  PubMed  CAS  Google Scholar 

  225. Sekine H, Fukui I, Yamada T, Ohwada F, Yokokawa M, Ohshima H (1994) Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: A longer followup result. J Urol 151: 27–30.

    PubMed  CAS  Google Scholar 

  226. Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H (1991) Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 138: 193–201.

    PubMed  CAS  Google Scholar 

  227. Sengelov L, Nielsen OS, Kamby C, von der Maase H (1995) Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Cancer 76: 1797–1803.

    Article  PubMed  CAS  Google Scholar 

  228. Sengelov L, von der Maase H (1999) Radiotherapy in bladder cancer. Radiother Oncol 52: 1–14.

    Article  PubMed  CAS  Google Scholar 

  229. Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A (1988) Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: Preliminary report. BrJ Urol 62: 558–564.

    Article  CAS  Google Scholar 

  230. Shipley WU, Cummings KB, Coombs LJ, Hawkins IR, Einstein AB, Penick G (1982) 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: A prospective study of patient tolerance and pathologic downstaging. J Urol 127: 48–51.

    PubMed  CAS  Google Scholar 

  231. Shipley WU, Prout Jr. GR, Einstein AB, et al. (1987a) Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. Jama 258: 931–935.

    Article  PubMed  CAS  Google Scholar 

  232. Shipley WU, Prout Jr. GR, Kaufman SD, Perrone TL (1987b) Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer 60: 514–520.

    Article  PubMed  CAS  Google Scholar 

  233. Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout Jr. GR (1985) Full-dose irradiation for patients with invasive bladder carcinoma: Clinical and histological factors prognostic of improved survival. J Urol 134: 679–683.

    PubMed  CAS  Google Scholar 

  234. Shipley WU, Winter KA, Kaufman DS, et al. (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03 [see Comments]. J Clin Oncol 16: 3576–3583.

    PubMed  CAS  Google Scholar 

  235. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B (1992) Clonal origin bladder cancer [see Comments]. N Engl J Med 326: 737–740.

    Article  PubMed  CAS  Google Scholar 

  236. Simon D, Yen S, Cole P (1975) Coffee drinking and cancer of the lower urinary tract. J Natl Cancer Inst 54: 587–591.

    PubMed  CAS  Google Scholar 

  237. Simoneau M, LaRue H, Fradet Y (1999) Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol Res 27: 180–184.

    Article  PubMed  CAS  Google Scholar 

  238. Skarlos DV, Aravantinos G, Linardou E, et al. (1997) Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study. Eur Urol 31: 420–27.

    PubMed  CAS  Google Scholar 

  239. Skinner DG (1982) Management of invasive bladder cancer: A meticulous pelvic node dissection can make a difference. J Urol 128: 34–36.

    PubMed  CAS  Google Scholar 

  240. Skinner DG, Boyd SD, Lieskovsky G (1984) Clinical experience with the Kock continent ileal reservoir for urinary diversion. J Urol 132: 1101–1107.

    PubMed  CAS  Google Scholar 

  241. Skinner DG, Boyd SD, Lieskovsky G, Bennett C, Hopwood B (1991a) Lower urinary tract reconstruction following cystectomy: Experience and results in 126 patients using the Kock ileal reservoir with bilateral ureteroileal urethrostomy. J Urol 146: 756–760.

    PubMed  CAS  Google Scholar 

  242. Skinner DG, Daniels JR, Russell CA, et al. (1991b) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 145: 459–464; Discussion 464-467.

    PubMed  CAS  Google Scholar 

  243. Skinner DG, Lieskovsky G (1984) Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131: 1069–1072.

    PubMed  CAS  Google Scholar 

  244. Skinner DG, Tift JP, Kaufman JJ (1982) High dose, short course preoperative radiation therapy and immediate single stage radical cystectomy with pelvic node dissection in the management of bladder cancer. J Urol 127: 671–674.

    PubMed  CAS  Google Scholar 

  245. Small EJ, Fippin LJ, Ernest ML, Carroll PR (1996) A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 78: 1775–1780.

    Article  PubMed  CAS  Google Scholar 

  246. Small EJ, Lew D, Redman BG, et al. (2000) Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point. J Clin Oncol 18: 2537–2544.

    PubMed  CAS  Google Scholar 

  247. Smith Jr. JA, Crawford ED, Paradelo JC, et al. (1997) Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study. J Urol 157: 805–807; Discussion 807-808.

    Article  PubMed  Google Scholar 

  248. Smith Jr. JA, Whitmore Jr. WF (1981 a) Regional lymph node metastasis from bladder cancer. J Urol 126:591–593.

    PubMed  Google Scholar 

  249. Smith Jr. JA, Whitmore Jr.Jr. WF (1981b) Salvage cystectomy for bladder cancer after failure of definitive irradiation. J Urol 125: 643–645.

    PubMed  Google Scholar 

  250. Sola C, Mallafre J, Mendoza Solorzano L, et al. (1993) Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma. Ann Oncol 4: 313–316.

    PubMed  CAS  Google Scholar 

  251. Soto EA, Friedell GH, Tiltman AJ (1977) Bladder cancer as seen in giant histologic sections. Cancer 39: 447–455.

    Article  PubMed  CAS  Google Scholar 

  252. Splinter TA, Pavone-Macaluso M, Jacqmin D, et al. (1996) Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: Prognostic factor analysis. Eur J Cancer 32A: 1129–1134.

    Article  PubMed  CAS  Google Scholar 

  253. Splinter TA, Scher HI, Denis L, et al. (1992) The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer — Genitourinary Group. J Urol 147: 606–608.

    PubMed  CAS  Google Scholar 

  254. Srougi M, Simon SD (1994) Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A 5-year followup. J Urol 151: 593–597.

    PubMed  CAS  Google Scholar 

  255. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394–3398.

    PubMed  CAS  Google Scholar 

  256. Stassar MJ, Vegt PD, Steerenberg PA, et al. (1994) Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol Res 22: 177–184.

    Article  PubMed  CAS  Google Scholar 

  257. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163: 761–767.

    Article  PubMed  CAS  Google Scholar 

  258. Sternberg CN (1996) Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 23: 621–632.

    PubMed  CAS  Google Scholar 

  259. Sternberg CN, Arena MG, Calabresi F, et al. (1993) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer 72: 1975–1982.

    Article  PubMed  CAS  Google Scholar 

  260. Sternberg CN, Pansadoro V, Calabro F, et al. (1999) Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder [see Comments]. Ann Oncol 10: 1301–1305.

    Article  PubMed  CAS  Google Scholar 

  261. Sternberg CN, Yagoda A, Scher HI, et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448–2458.

    Article  PubMed  CAS  Google Scholar 

  262. Stemberg CN, Yagoda A, Scher HI, et al. (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461–469.

    Google Scholar 

  263. Stockle M, Meyenburg W, Wellek S, et al. (1995) Adjuvant polychemotherapy of nonorgan-conflned bladder cancer after radical cystectomy revisited: Long-term results of a controlled prospective study and further clinical experience. J Urol 153: 47–52.

    Article  PubMed  CAS  Google Scholar 

  264. Stoter G, Splinter TA, Child JA, et al. (1987) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663–667.

    PubMed  CAS  Google Scholar 

  265. Studer UE, Bacchi M, Biedermann C, et al. (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial. J Urol 152:81–84.

    PubMed  CAS  Google Scholar 

  266. Sweeney CJ, Williams SD, Finch DE, et al. (1999) A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86:514–518.

    Article  PubMed  CAS  Google Scholar 

  267. Sylvester R, Sternberg C (2000) The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why [In Process Citation]. Ann Oncol 11: 851–856.

    Article  PubMed  CAS  Google Scholar 

  268. Takashi M, Nagai T, Murase T, Miyake K, Hamajima N, Mizuno S (1989) Multivariate evaluation of determinants affecting regional lymph node metastasis and survival in bladder cancer patients who underwent radical cystectomy. Urol Int 44: 125–131.

    Article  PubMed  CAS  Google Scholar 

  269. Tester W, Caplan R, Heaney J, et al. (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 119–126.

    PubMed  CAS  Google Scholar 

  270. Tester W, Porter A, Asbell S, et al. (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25: 783–790.

    Article  PubMed  CAS  Google Scholar 

  271. Thompson IM (1987) The evaluation of microscopic hematuria: A population-based study. J Urol 138: 1189–1190.

    PubMed  CAS  Google Scholar 

  272. Tolley DA, Parmar MK, Grigor KM, et al. (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up. J Urol 155: 1233–1238.

    Article  PubMed  CAS  Google Scholar 

  273. Torti FM, Shortliffe LD, Williams RD, et al. (1988) Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study. J Clin Oncol 6: 476–483.

    PubMed  CAS  Google Scholar 

  274. Tsai YC, Simoneau AR, Spruck 3rd CH, et al. (1995) Mosaicism in human epithelium: Macroscopic monoclonal patches cover the urothelium. J Urol 153: 1697–1700.

    Article  PubMed  CAS  Google Scholar 

  275. Utz DC, Hanash KA, Farrow GM (1970) The plight of the patient with carcinoma in situ of the bladder. J Urol 103: 160–164.

    PubMed  CAS  Google Scholar 

  276. Utz DC, Schmitz SE, Fugelso PD, Farrow GM (1973) Proceedings: A clinicopatho-logic evaluation of partial cystectomy for carcinoma of the urinary bladder. Cancer 32:1075–1077.

    Article  PubMed  CAS  Google Scholar 

  277. Van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, De Balincourt C (1999) Significance of bladder biopsies in Ta,T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 35: 267–271.

    Article  PubMed  Google Scholar 

  278. Van der Werf-Messing B, Menon RS, Hop WC (1983) Carcinoma of the urinary bladder category T3NxMo treated by the combination of radium implant and external irradiation: Second report. Int J Radiat Oncol Biol Phys 9: 177–180.

    Article  PubMed  Google Scholar 

  279. Varveris H, Delakas D, Anezinis P, et al. (1997) Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 17:4771–4780.

    PubMed  CAS  Google Scholar 

  280. Vaughn DJ, Malkowicz SB, Zoltick B, et al. (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol 16: 255–260.

    PubMed  CAS  Google Scholar 

  281. Vegt PD, Van der Meijden AP, Sylvester R, Brausi M, Holtl W, De Balincourt C (1997) Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 157: 1246–1249.

    Article  PubMed  CAS  Google Scholar 

  282. Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, Van der Meijden AP (1995) A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pTl papillary carcinoma and carcinoma in situ of the bladder. J Urol 153: 929–933.

    Article  PubMed  CAS  Google Scholar 

  283. Vikram B, Chadha M, Malamud SC, Hecht H, Grabstald H (1998) Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: Long term results of a pilot study. Cancer 82: 918–922.

    Article  PubMed  CAS  Google Scholar 

  284. Vogelzang NJ, Moormeier JA, Awan AM, et al. (1993) Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: The University of Chicago experience. J Urol 149: 753–757.

    PubMed  CAS  Google Scholar 

  285. Von der Maase H, Hansen SW, Roberts JT, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068–3077.

    PubMed  Google Scholar 

  286. Wei CH, Hsieh RK, Chiou TJ, Chen KK, Chang LS, Chen PM (1996) Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience [see Comments]. J Urol 155: 118–121.

    Article  PubMed  CAS  Google Scholar 

  287. Weldon TE, Soloway MS (1975) Susceptibility of urothelium to neoplastic cellular implantation. Urology 5: 824–827.

    Article  PubMed  CAS  Google Scholar 

  288. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP (1998a) Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer [see Comments]. J Urol 160: 1668–1671; Discussion 1671-1672.

    Article  PubMed  CAS  Google Scholar 

  289. Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM (1993) Use of maintenance intravesical bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol Int 51: 67–72.

    Article  PubMed  CAS  Google Scholar 

  290. Witjes JA, Van der Meijden AP, Sylvester LC, Debruyne FM, Van Aubel A, Witjes WP (1998b) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52: 403–410.

    Article  PubMed  CAS  Google Scholar 

  291. Witte RS, Elson P, Bono B, et al. (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15: 589–593.

    PubMed  CAS  Google Scholar 

  292. Wood Jr. DP, Montie JE, Pontes JE, Levin HS (1989) Identification of transitional cell carcinoma of the prostate in bladder cancer patients: A prospective study. J Urol 142: 83–85.

    PubMed  Google Scholar 

  293. Younes M, Sussman J, True LD (1990) The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66: 543–548.

    Article  PubMed  CAS  Google Scholar 

  294. Zielinski CC, Schnack B, Grbovic M, et al. (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial. Br J Cancer 78: 370–374.

    Article  PubMed  CAS  Google Scholar 

  295. Zincke H, Benson Jr. RC, Hilton JF, Taylor WF (1985) Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: A prospective, randomized, stratified study with crossover design. J Urol 134: 1110–1114.

    PubMed  CAS  Google Scholar 

  296. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ (1983) Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double-blind, controlled trial. J Urol 129: 505–509.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Onkologie und Ludwig-Boltzmann-Institut für klinisch-experimentelle Onkologie, Universitätsklinik für Innere Medizin I, Allgemeines Krankenhaus, Währinger Gürtel 18-20, A-1090, Wien, Österreich

    Dr. Wolfgang J. Köstler & Univ.-Prof Dr. Christoph C. Zielinski (Extraordinariat für internistisch-experimentelle Onkologie)

Authors
  1. Dr. Wolfgang J. Köstler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Univ.-Prof Dr. Christoph C. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I, Allgemeines Krankenhaus, Wien, Österreich

    Christoph Zielinski

  2. Klinische Abteilung für Allgemeinchirurgie, Univ.-Klinik für Chirurgie, Allgemeines Krankenhaus, Wien, Österreich

    Raimund Jakesz

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Wien

About this chapter

Cite this chapter

Köstler, W.J., Zielinski, C.C. (2001). Blasencarcinome und Carcinome des Übergangsepithels. In: Zielinski, C., Jakesz, R. (eds) Urogenitale Carcinome. Onkologie heute. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6193-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6193-7_7

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83528-9

  • Online ISBN: 978-3-7091-6193-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation